Anees B. Chagpar, MD, MSc, MA, MPH
In the last decade, sentinel lymph node biopsy has become established as an alternative to axillary lymph node dissection for nodal staging in patients with early-stage breast cancer, as a result of several randomized trials showing similar disease-free and overall survival of these two procedures,1,2
as well as less morbidity (such as reduced arm lymphedema and sensory deficits) and improved quality of life with sentinel lymph node surgery.3,4
With increasing use of neoadjuvant chemotherapy, however, controversy has erupted regarding the optimal timing of this procedure. Some argue that sentinel node biopsy prior to neoadjuvant chemotherapy provides the most accurate staging, whereas others argue that performing a sentinel node biopsy after neoadjuvant chemotherapy could allow patients with node-positive disease who achieve a pathologic complete response to avoid the morbidity of an axillary node dissection. Anees B. Chagpar, MD, MSc, MA, MPH, associate professor of Surgery at Yale University and director of The Breast Center—Smilow Cancer Hospital at Yale-New Haven, discussed this issue at the 30th Annual Miami Breast Cancer Conference.
Arguments Against Delaying Sentinel Lymph Node Biopsy
The primary objection to delaying sentinel node surgery until after neoadjuvant chemotherapy is its false-negative rate. In 2006, a meta-analysis of nearly 1300 patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy reported a false-negative rate of 12%,5
and a 2012 presentation of the ACOSOG Z1071 trial, which also examined the procedure after neoadjuvant chemotherapy, reported a false-negative rate of 12.6%.6
This is in contrast to the 5% to 9.5% false-negative rate reported when the sentinel node procedure is performed prior to any therapy.2,7,8
It has been hypothesized that the elevated falsenegative rate with delayed sentinel node surgery may be caused by uneven sterilization of the lymph nodes by the chemotherapy; certainly, it raises concern about the impact of this residual disease on the locoregional recurrence rate. When performed after neoadjuvant chemotherapy, sentinel lymph node biopsy also has a poorer identification rate of the sentinel lymph node than when it is performed prior to chemotherapy (87% vs 97%-100%).9
This decreased identification rate is postulated to be caused by structural changes in lymphatic drainage, such as fibrosis within the axilla.10
Finally, pretreatment determination of the pathological status of the lymph nodes can impact decisions regarding postoperative radiation therapy, and this information would be unavailable to patients who delayed sentinel node biopsy until after receiving chemotherapy.
Arguments for Delaying Sentinel Lymph Node Biopsy Proponents of performing sentinel lymph node biopsy after chemotherapy acknowledge both the lower sentinel node identification rate and the higher false-negative rate of this approach, but propose that both are reasonable. “Risk, like beauty,” Chagpar said, “is in the eye of the beholder. For some, the false-negative rate of 12% is too high; for others, it is acceptable.” She argued that there is less worry about residual disease in recent years, with regard to both its impact on locoregional recurrence and survival. For instance, the randomized NSABP B-04 trial, which was designed to determine whether outcomes would be compromised when the extent of surgery was reduced (from radical mastectomy), demonstrated that locoregional recurrences in the arm with the least extensive surgery (having no targeted axillary treatment) produced no worsening of overall survival.11
This suggests that the surgical resection of additional lymph nodes may have little to no impact on survival. It is also true that the timing of axilla staging in patients with locally advanced disease has minimal influence on the type of chemotherapy they will receive, and while upfront sentinel node biopsy may influence the decision to provide post-mastectomy radiation therapy, many of these patients would qualify for radiation therapy on the basis of tumor size alone.